GI Innovation
Financials
Valuation Metrics
GI Innovation's Market Cap is ₩5516B. At end of 2025 it was ₩1.1T. Ranked #428 of 2,436 in KR market (top 18%), #146 of 1,649 on KOSDAQ (top 9%), #50 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 21%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 551.61B KRW | KR#428/2,436 Sec#50/234 |
| Revenue | 5.63B KRW | KR#2,337/2,436 Sec#192/234 |
| Net Income | -34.65B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 116.12B KRW | KR#1,638/2,436 Sec#133/234 |
| Net Assets | 107.80B KRW | KR#1,344/2,436 Sec#109/234 |
| Employees | 84 | KR#1,763/2,436 Sec#142/234 |
| Value | ||
| P/B | 5.12x | KR#2,241/2,436 Sec#187/234 |
| P/S | 98.05x | KR#2,388/2,436 Sec#210/234 |
| FCF Yield | -7.19% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -32.14% | KR#2,180/2,436 Sec#177/234 |
| ROA | -29.84% | KR#2,300/2,436 Sec#199/234 |
| Op. Margin | -731.84% | KR#2,383/2,436 Sec#212/234 |
| Revenue Growth | -100.00% | KR#2,349/2,436 Sec#214/234 |
| Financial Health | ||
| Debt Ratio | 107.72% | KR#388/2,436 Sec#55/234 |
| Total Debt | 1.65B KRW | KR#1,916/2,436 Sec#185/234 |
| FCF | -39.68B KRW | KR#2,045/2,436 Sec#202/234 |
| Cash | 24.82B KRW | KR#1,114/2,436 Sec#77/234 |
| Current Ratio | 4.69x | KR#323/2,436 Sec#61/234 |
| Performance | ||
| 1Y Return | -51.97% | KR#2,112/2,436 Sec#198/234 |
| 1M Return | -4.89% | KR#1,388/2,436 Sec#143/234 |
| From 52W High | -59.76% | KR#1,701/2,436 Sec#142/234 |
| 1Y MDD | -67.97% | KR#1,852/2,436 Sec#158/234 |
| Trading | ||
| Volume | 633,450 shares | KR#216/2,436 Sec#18/234 |
| Trading Value | 5.36B KRW | KR#346/2,436 Sec#40/234 |
| Foreign Own. | 8.69% | KR#530/2,436 Sec#46/234 |
| Per Share | ||
| EPS | -546 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,678 KRW | KR#2,120/2,436 Sec#181/234 |
Company Info
GI Innovation, established in 2017, is a specialized fusion protein-based new drug research and development company that listed on KOSDAQ under special provisions in 2023. It boasts a diverse pipeline of immune therapeutics, including immuno-oncology drugs and allergy treatments, facilitated by its GI-SMART platform technology for one-stop early discovery. The company has completed technology transfers to Simcere and Yuhan Corporation and entered into a joint clinical trial agreement with MSD, contributing to the creation of a global innovative new drug pipeline. GI Innovation is headquartered in Songpa-gu, Seoul.